Celiprolol for Ehlers-Danlos Syndrome
(DiSCOVER Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing celiprolol, a medication, in patients with a genetic condition called COL3A1-positive vEDS. The goal is to see if it can make their blood vessels stronger and reduce medical issues related to their condition. Celiprolol has shown protective effects in patients with vascular Ehlers-Danlos syndrome (vEDS).
Will I have to stop taking my current medications?
You will need to stop taking β-blockers (a type of heart medication) before joining the trial. The protocol does not specify about other medications.
How does the drug Celiprolol differ from other treatments for Ehlers-Danlos Syndrome?
Celiprolol is unique for Ehlers-Danlos Syndrome because it is a beta-blocker that may help strengthen blood vessels, which is particularly important for this condition that affects connective tissue. Unlike other treatments, Celiprolol specifically targets the cardiovascular complications associated with Ehlers-Danlos Syndrome, offering a novel approach compared to general supportive care.12345
What data supports the effectiveness of the drug celiprolol for treating vascular Ehlers-Danlos syndrome?
Research shows that celiprolol, a type of beta-blocker, significantly reduces the risk of arterial events like dissections and ruptures in patients with vascular Ehlers-Danlos syndrome. This drug helps by lowering heart rate and pressure, which reduces stress on the arteries, and has shown significant benefits in clinical trials.678910
Are You a Good Fit for This Trial?
This trial is for individuals with genetically confirmed vascular Ehlers-Danlos Syndrome (vEDS) who are at least 15 years old. Participants must not have had certain medical events like arterial rupture in the past 6 months, be pregnant, or use β-blockers within 28 days prior to starting the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either celiprolol or placebo in a double-blind manner, with titration over the first 4 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term with celiprolol
What Are the Treatments Tested in This Trial?
Interventions
- Celiprolol
Celiprolol is already approved in European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Acer Therapeutics Inc.
Lead Sponsor